clinical trial · NCT06399172
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
OncoSil Medical Limited·—·not yet recruiting·n = 50
Locally Advanced Pancreatic AdenocarcinomaOncoSil
brief summary
The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.
started
May 30, 2024
primary completion
May 30, 2029
completion
Oct 30, 2029
last updated
May 3, 2024
official title
OncoSil Pancreatic Cancer Post-marketing Clinical Registry Italy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol